Revance Therapeutics reported $106.5M in Operating Expenses for its third fiscal quarter of 2022.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Operating Expenses Change
Abbvie ABBV:US USD 10.21B 1.08B
Aerie Pharmaceuticals AERI:US USD 62.8M 11.35M
ALKERMES ALKS:US USD 313M 2.32M
Bristol Myers Squibb BMY:US USD 8.75B 552M
Cara Therapeutics CARA:US USD 34.66M 7.18M
Coherus Biosciences CHRS:US USD 125.87M 21.71M
Eli Lilly And LLY:US USD 5.27B 12.8M
Endo International Ordinary Shares ENDP:US USD 1.18B 1.13B
Horizon Pharma HZNP:US USD 764.75M 23.1M
JAZZ PHA JAZZ:US USD 915.89M 68.56M
Johnson & Johnson JNJ:US USD 17.97B 211M
Merk MRK:US USD 10.97B 1.31B
Neurocrine Biosciences NBIX:US USD 300.1M 93.4M
Pacira Pharmaceuticals PCRX:US USD 146.18M 8M
Procter & Gamble PG:US USD 15.67B 244M
Revance Therapeutics RVNC:US USD 106.5M 20.29M
Supernus Pharmaceuticals SUPN:US USD 178.88M 20.17M
Teva Pharmaceutical Industries TEVA:US USD 3.18B 1.56B